Evidence map›Paper›PMID 19319189›Full record

ArticlePloS one2009

Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector.

Francis S Willard, Melinda D Willard, Adam J Kimple, Meera Soundararajan, Emily A Oestreich, Xiaoyan Li, Nathaniel A Sowa, Randall J Kimple, Declan A Doyle, Channing J Der and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. The Intricacies of Renal Phosphate Reabsorption-An Overview.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. RGS14 Regulation of Post-Synaptic Signaling and Spine Plasticity in Brain.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. RGS14 regulates the lifetime of GPharmacology research & perspectives · 2016
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Francis S WillardDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Melinda D Willard
Adam J Kimple
Meera Soundararajan
Emily A Oestreich
Xiaoyan Li
Nathaniel A Sowa
Randall J Kimple
Declan A Doyle
Channing J Der
Mark J Zylka
William D Snider
David P Siderovski
University of North Carolina at Chapel Hill · USGenomics (United Kingdom) · GBUNC Lineberger Comprehensive Cancer CenterUniversity of Oxford · GB

Funding

Biochemical Modulation of Nociceptive CircuitsR01NS060725 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2007 to 2010
$1.3M
Role of RGS proteins in Ras- and B-Raf--mediated transformationR01CA127152 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2007 to 2011
$1.1M
Mechanistic studies of a novel G-alpha nucleotide cycleR01GM074268 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SIDEROVSKI, DAVID P. · 2006 to 2009
$902k
NCI NIH HHS R01 CA127152NCI NIH HHS R01CA127152NIGMS NIH HHS R01 GM074268NIGMS NIH HHS R01GM074268NINDS NIH HHS R01 NS060725NINDS NIH HHS R01NS060725Wellcome Trust
6 · The paper itself

Abstract

backgroundRegulator of G-protein signaling (RGS) proteins have been well-described as accelerators of Galpha-mediated GTP hydrolysis ("GTPase-accelerating proteins" or GAPs). However, RGS proteins with complex domain architectures are now known to regulate much more than Galpha GTPase activity. RGS14 contains tandem Ras-binding domains that have been reported to bind to Rap- but not Ras GTPases in vitro, leading to the suggestion that RGS14 is a Rap-specific effector. However, more recent data from mammals and Drosophila imply that, in vivo, RGS14 may instead be an effector of Ras. METHODOLOGY/PRINCIPAL

findingsFull-length and truncated forms of purified RGS14 protein were found to bind indiscriminately in vitro to both Rap- and Ras-family GTPases, consistent with prior literature reports. In stark contrast, however, we found that in a cellular context RGS14 selectively binds to activated H-Ras and not to Rap isoforms. Co-transfection / co-immunoprecipitation experiments demonstrated the ability of full-length RGS14 to assemble a multiprotein complex with components of the ERK MAPK pathway in a manner dependent on activated H-Ras. Small interfering RNA-mediated knockdown of RGS14 inhibited both nerve growth factor- and basic fibrobast growth factor-mediated neuronal differentiation of PC12 cells, a process which is known to be dependent on Ras-ERK signaling. CONCLUSIONS/SIGNIFICANCE: In cells, RGS14 facilitates the formation of a selective Ras.GTP-Raf-MEK-ERK multiprotein complex to promote sustained ERK activation and regulate H-Ras-dependent neuritogenesis. This cellular function for RGS14 is similar but distinct from that recently described for its closely-related paralogue, RGS12, which shares the tandem Ras-binding domain architecture with RGS14.

Indexed as

AnimalsBinding SitesCell DifferentiationExtracellular Signal-Regulated MAP KinasesFibroblast Growth Factor 2HumansMiceMitogen-Activated Protein KinasesMultiprotein ComplexesNerve Growth FactorNeuritesPC12 CellsProtein Bindingraf Kinasesras ProteinsRatsExtracellular Signal-Regulated MAP KinasesFibroblast Growth Factor 2Mitogen-Activated Protein KinasesMultiprotein ComplexesNerve Growth Factorraf Kinasesras ProteinsRgs14 protein, ratRGS Proteins

Identifiers

PMID19319189
PMCPMC2655719
OpenAlexW2048788153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.